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Dr Joseph F. Sabik (Cleveland, Ohio). I would like to congrat-
ulate Dr Ferguson and colleagues on a fine presentation and study
and thank them for providing me with a copy of their report in
advance of the meeting.
As we heard, the authors used NIRF-CAPA to evaluate the
functional importance of coronary artery stenosis by comparing
myocardial perfusion before and after CABG. They found that
despite significant coronary artery stenosis by angiography, bypass
grafting did not improve myocardial perfusion in slightly>20% of
the territories grafted, suggesting to the authors that these stenoses
were not functionally significant and therefore did not need
grafting and that grafting them might have led to harm. I have a
few questions for the authors.
My first question has to dowith the usefulness of this technique.
Whether coronary artery stenosis is physiologically significant is
important to know before grafting. With this technique, the
functional significance of the stenosis is determined only after
the artery has been grafted. How can this technique guide in
decision-making as the title of your presentation suggests?
My second question has to do with whether measuring changes
in myocardial perfusion without stress is an accurate method of
determining the functional significance of a coronary blockage.
The physiologic test used to determine the functional importance
of coronary artery stenosis is to provoke the myocardium with
stress. For instance, during the measurement of a functionally
significant coronary stenosis using FFR, a vasodilator, such as
adenosine, is given to induce hyperemia before measuring the
decrease in perfusion across the stenosis. In your measurement
of myocardial perfusion, no stressing of the myocardium has
been done either before or after grafting. For example, for the
procedures done on pump, the blood flow measurements were
made with the patient still on cardiopulmonary bypass, a very
low workload on the myocardium. Is it not possible that this
method might have underestimated the functional significance of
the coronary stenosis?
My third question is, because of studies such as FAME 1
and FAME 2, the importance of not stenting nonphysiologicrdiovascular Surgery c Volume 146, Number 4 833
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your report, you extrapolated these findings to also apply to
coronary artery bypass grafting. These 2 revascularization
techniques are very different, and one could hypothesize that
grafting a nonphysiologic stenosis might result in only the graft
closing, with no resultant harm to the patient. In your report, you
showed excellent results for the entire group of patients. Did
you compare the outcomes in the patients with grafts that did
not increase myocardial perfusion with those with grafts that
did increase myocardial perfusion, and if you did, were there
any differences?
My final question has to do with the FFR data that were
collected preoperatively for some patients. Were you able to
determine whether the FFR data you had correlated with your
findings of myocardial perfusion after grafting?
I would once again like to congratulate the authors for an
interesting study and thank the Association for the opportunity
of discussing this report.
Dr Ferguson. Thank you, Dr Sabik, and thank you for your
comments.
After 50 years, the anatomic basis for CABG is changing. We
are moving to an era in which the functionality of target vessel
coronary artery stenoses are going to be characterized in the
catheterization laboratory before patients come to surgery. In
fact, we are going to be faced with a situation in which the
cardiologists tell us to graft this stenosis based on functionality
but do not graft this stenosis based on nonfunctionality. FFR
introduces physiology into the catheterization laboratory, and we
need a method in the operating room to be able to evaluate the
physiologic response to revascularization and to validate the
preoperative results to be able to determine that a patient has
received the full benefit of this operation. This physiologic
evolution certainly seems to be the trend and was the genesis for
the National Heart, Lung, Blood Institute Cardiac Surgical
Network FFR-guided CABG trial that is under discussion and
other trials such as FAME 3 that are under discussion.
With regard to your second question, this is definitely not a
stress evaluation of the myocardium, unlike FFR. This evaluation
is done during a 90-second period in which the heart rate, blood
pressure, and coronary autoregulation are stable to obtain both
the pregrafting image and the postgrafting image.We spent several
years developing and validating that this is the case. Thus, what
you see is a direct comparison, which is the difference in flow
down the epicardial coronary versus the epicardial coronary plus
the graft, and the consequent effect on myocardial perfusion.
Currently, the only correlation with the maximal vasodilation
circumstance with FFR is that 23% of these imaged grafts do
not show a regional myocardial perfusion increase, 20% of the
anatomic lesions between 71% and 90% in FAME did not have
functionality associated with them, and 20% to 25% of the grafts
that we sew have been occluded silently at 1 year, as determined
by protocol-driven angiography in most of our major studies.
As to your third question, we do not yet have formal long-term
follow-up on the fate of the grafts without an increase in perfusion.
In these multivessel CABG patients, however, essentially all
patients in the group had some measured increase in regional
perfusion. At the other end of the spectrum, the number of patients
with a substantial increase in all regions was relatively small,834 The Journal of Thoracic and Cardiovascular Surgapproximately 15% to 20%. The short-term outcomes were
excellent, and the absence of a perfusion increase on a per graft
basis was not associated with acute perioperative events based
on the present analysis.
Addressing your fourth question, we do have data, not yet
published, considering the correlation of the regional myocardial
perfusion change, anatomy, and myocardial ischemia. When
perfusion change is compared with the SYNTAX-characterized
anatomy alone, the correlation was not statistically significant.
If one adds the functionality of the myocardium, from the
FFR, preoperative magnetic resonance imaging level, or clinical
status, that relationship becomes highly significant, suggest-
ing that the measurement of regional myocardial perfusion
change at surgery is an index of the relief of ischemia or the
relief of the perfusion deficit measured preoperatively in these
patients.
Dr Sabik. I would just like to add a word of caution about
FFR-guided surgical revascularization. Some studies have now
shown that if one grafts a vessel that has an FFR>8, only 1 of 5
of those grafts are going to close; 8 of the 10, or 80%, are going
to remain open; and we know that the vessels that cause myocar-
dial infarction are those moderate lesions that thrombose. When
we consider surgery, we are thinking about a long-term solution
to a problem, and those 80% of grafts might very well be protective
over the long run. Also, whenwe think about FFR and stenting, it is
really owing to the periprocedural complications and the restenosis
why stenting does not work. Finally, I just worry that if we
extrapolate the findings of FAME to surgery, we might be doing
80% of our patients harm.
Dr Ferguson. I actually completely agree with you, Joe. This
study is not advocating adopting an FFR-guided strategy for
revascularization. It is advocating imaging of the physiologic
consequences of revascularization in the operating room to learn
how we can improve CABG from a physiologic perspective,
beyond using the anatomy alone.
For example, the late mortality from FREEDOM and SYNTAX
cannot be explained by the anatomy, because both arms of the
intervention in both of those trials were anatomically based.
Thus, something else besides anatomy must be driving the long-
term survival benefit in those patients. Our data suggest that it
might be the functional response to bypass surgery that we have
been creating all along. Understanding the cause of this benefit
will be important in the evolving, physiologic-based revasculariza-
tion era beyond anatomy alone.
Dr John H. Calhoon (San Antonio, Tex). Elegant study. To
continue with what Dr Sabik said, how are you going to use this
technique to help us know how to do CABG or more appropriate
CABG when we are considering the 10-year survival for the
operating room as opposed to the 10-minute outcome in the
catheterization laboratory? I am afraid that this technology falls
into the same category that Joe described, we are considering
use of a technology designed to help cardiologists know when to
intervene on a lesion rather than to help us know what to do for
a patient long term. In other words, how might this technology
be applied successfully in CABG?
Dr Ferguson. The newwindow here is a window of opportunity
into the physiology of revascularization that we accomplish in the
operating room.ery c October 2013
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flow in bypass grafts is potentially a very real asset in our
ability to learn what the influence of competitive flow on
long-term graft survival actually is, because right now we do
not know.
Using the traditional anatomic construct for CABG, we do a
number of tasks based on assumptions but not real data, because
we have never measured it in the operating room.The Journal of Thoracic and CaAs I stated, the idea that something other than anatomy is what
drives the long-term survival from SYNTAX and FREEDOM
trials might be directly linked to what we create functionally at
surgery, which is a safety net of perfusion. Linking the preopera-
tive functional anatomy and long-term outcomes will greatly be
facilitated by the intraoperative assessment of the physiologic
consequences of revascularization, which could be the physiologic
substrate for long-term survival benefit in CABG.rdiovascular Surgery c Volume 146, Number 4 835
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